COVID-19 (coronavirus)

Alzheimer's Disease

Preclinical Research

Retinal Imaging

Acta Neuropathlogical

Early diagnosis and immune-based therapies

Figure 1. Retinal amyloid pathology in AD patients. Increased retinal Aβ42 deposition correlates with cerebral amyloid plaque burden in Alzheimer’s patients. From the Koronyo-Hamaoui Lab: Koronyo, et al., JCI Insight. 2017.

Figure 1. Retinal amyloid pathology in AD patients. Increased retinal Aβ42 deposition correlates with cerebral amyloid plaque burden in Alzheimer’s patients. From the Koronyo-Hamaoui Lab: Koronyo, et al., JCI Insight. 2017.

Figure 2. Synaptic and neurite preservation from toxic Aβ1-42 oligomers obtained by GA-activated monocyte-derived macrophages. Red: a macrophage expressing high levels of scavenger receptor; Green: Aβ1-42 oligomers; White: Neuronal processes (in primary neuronal culture). From the Koronyo-Hamaoui Lab: Li, et al., Front. Immunol. 2020.

Figure 2. Synaptic and neurite preservation from toxic Aβ1-42 oligomers obtained by GA-activated monocyte-derived macrophages. Red: a macrophage expressing high levels of scavenger receptor; Green: Aβ1-42 oligomers; White: Neuronal processes (in primary neuronal culture). From the Koronyo-Hamaoui Lab: Li, et al., Front. Immunol. 2020.

Visual deficits in animal models

Figure 3 Koronyo-Hamaoui's visual stimuli 4-arm x-maze (ViS4M) to assess color and contrast vision in animal models of aging and Alzheimer's disease. Illustration courtesy of ConductScience/MazeEngineers (2021); From Koronyo-Hamaoui Lab: Vit, et al., Sci Rep. 2021.

Figure 3. Koronyo-Hamaoui's visual stimuli 4-arm x-maze (ViS4M) to assess color and contrast vision in animal models of aging and Alzheimer's disease. Illustration courtesy of ConductScience/MazeEngineers (2021); From Koronyo-Hamaoui Lab: Vit, et al., Sci Rep. 2021.  

Figure 4. Retinal vasculopathy in Alzheimer's disease. From Koronyo-Hamaoui Lab: Left image: Shi, et al., Acta Neuropathologica. 2020. Right image: Shi, et al., ANP Commun. 2020.

Figure 4. Retinal vasculopathy in Alzheimer's disease. From Koronyo-Hamaoui Lab: Left image: Shi, et al., Acta Neuropathologica. 2020. Right image: Shi, et al., ANP Commun. 2020.

Figure 5. Therapeutic effects of infusing bone marrow-derived monocytes from a young healthy mouse to an Alzheimer's-model mouse, mitigation of brain pathology and restoration of cognitive abilities. From Koronyo-Hamaoui Lab: Koronyo et al., Brain 2015

Figure 5. Therapeutic effects of infusing bone marrow-derived monocytes from a young healthy mouse to an Alzheimer's-model mouse, mitigation of brain pathology and restoration of cognitive abilities. From Koronyo-Hamaoui Lab: Koronyo et al., Brain 2015

Figure 6. Enhanced capabilities of ACE-overexpressing monocytes and macrophages to curb Alzheimer's pathology and restore cognitive function. From Koronyo-Hamaoui Lab: Bernstein, et al., JCI.2014.

Figure 6. Enhanced capabilities of ACE-overexpressing monocytes and macrophages to curb Alzheimer's pathology and restore cognitive function. From Koronyo-Hamaoui Lab: Bernstein, et al., JCI.2014.

Figure 7. BM transplantation or Blood Infusion with ACE-overexpressing (ACE10) monocytes were found to be highly neuroprotective and prevent cognitive loss in Alzheimer's-model mice. From: Koronyo-Hamaoui,et al.,Brain. 2020.

Figure 7. BM transplantation or Blood Infusion with ACE-overexpressing (ACE10) monocytes were found to be highly neuroprotective and prevent cognitive loss in Alzheimer's-model mice. From: Koronyo-Hamaoui,et al., Brain. 2020.

Regenerative Medicine

Clinical Research

Figure 8. Retinal amyloid imaging in MCI and AD patients was developed by the Koronyo-Hamaoui Lab and NeuroVision Imaging. Adopted from: Dumitrascu, et al., Alzheimer & Demen. (Amst.) 2020.

Figure 8. Retinal amyloid imaging in MCI and AD patients was developed by the Koronyo-Hamaoui Lab and NeuroVision Imaging. Adopted from: Dumitrascu, et al., Alzheimer & Demen. (Amst.) 2020.

Collaborations

Clinical Trials

Health Services Research

The medical care for persons living with Alzheimer’s disease and other forms of dementia is complex and involves a team of health providers and transitions between different sites of care. Our health services research explores innovative ways to achieve the Institute for Healthcare Improvement (IHI) triple aim of better patient outcomes (population health), better experience of care (patient satisfaction) and better value of care. Areas of active investigation include interventions to improve identification of persons with dementia in the clinic, emergency department and the hospital, improving quality and efficiency of dementia care and reduction of rehospitalization rates for hospitalized persons living with dementia.  

Memory & Aging Program

The Memory & Aging Program is a comprehensive population health approach to the care of persons living with dementia. The interventions span the early identification and intervention of persons-at-risk through health screening to the expert management of challenges associated with moderate to late-stage disease. The novel CEDARS-6 tool enables a personalized care path for persons living with dementia, their families/caregivers and health providers. We are exploring the acceptability and effectiveness of this approach to Alzheimer’s disease health delivery in achieving the triple aim.

Brain Health Initiative

With the recent discovery that the disease process for Alzheimer’s disease starts as early as 20 years before the appearance of the first symptom, the Centers for Disease Control and Prevention (CDC), the Alzheimer’s Association and the National Institutes of Health (NIH) have identified Alzheimer’s prevention and risk reduction to be an important area of dementia research. We are investigating the role of modifiable lifestyle factors including cardiovascular risk (blood pressure, diabetes, smoking), physical activity, nutrition, social interactions and sleep in mitigating the risk for developing Alzheimer’s disease.  

The Goldrich Center Potential Participant Registry

Are you interested in participating in brain research? We are looking for people who want to contribute to our understanding of brain health, aging and neurodegenerative conditions like Alzheimer’s disease.